These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 27390687)

  • 21. Cardiovascular Safety of Degarelix Versus Leuprolide in Patients With Prostate Cancer: The Primary Results of the PRONOUNCE Randomized Trial.
    Lopes RD; Higano CS; Slovin SF; Nelson AJ; Bigelow R; Sørensen PS; Melloni C; Goodman SG; Evans CP; Nilsson J; Bhatt DL; Clarke NW; Olesen TK; Doyle-Olsen BT; Kristensen H; Arney L; Roe MT; Alexander JH;
    Circulation; 2021 Oct; 144(16):1295-1307. PubMed ID: 34459214
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and safety of degarelix in patients with prostate cancer: Results from a phase III study in China.
    Sun Y; Xie L; Xu T; Jakobsen JS; Han W; Sørensen PS; Wang X
    Asian J Urol; 2020 Jul; 7(3):301-308. PubMed ID: 32742930
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Degarelix.
    Frampton JE; Lyseng-Williamson KA
    Drugs; 2009 Oct; 69(14):1967-76. PubMed ID: 19747011
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Gonadotropin-releasing hormone: an update review of the antagonists versus agonists.
    Van Poppel H; Klotz L
    Int J Urol; 2012 Jul; 19(7):594-601. PubMed ID: 22416801
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Gonadotropin-releasing hormone antagonist: A real advantage?
    Kimura T; Sasaki H; Akazawa K; Egawa S
    Urol Oncol; 2015 Jul; 33(7):322-8. PubMed ID: 26070474
    [TBL] [Abstract][Full Text] [Related]  

  • 26. An update on the use of degarelix in the treatment of advanced hormone-dependent prostate cancer.
    Rick FG; Block NL; Schally AV
    Onco Targets Ther; 2013; 6():391-402. PubMed ID: 23620672
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Degarelix and its therapeutic potential in the treatment of prostate cancer.
    Doehn C; Sommerauer M; Jocham D
    Clin Interv Aging; 2009; 4():215-23. PubMed ID: 19503784
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Degarelix versus goserelin (+ antiandrogen flare protection) in the relief of lower urinary tract symptoms secondary to prostate cancer: results from a phase IIIb study (NCT00831233).
    Anderson J; Al-Ali G; Wirth M; Gual JB; Gomez Veiga F; Colli E; van der Meulen E; Persson BE
    Urol Int; 2013; 90(3):321-8. PubMed ID: 23258223
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evaluation of degarelix in the management of prostate cancer.
    Van Poppel H
    Cancer Manag Res; 2010 Jan; 2():39-52. PubMed ID: 21188095
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cardiovascular Safety of Degarelix Versus Leuprolide for Advanced Prostate Cancer: The PRONOUNCE Trial Study Design.
    Melloni C; Slovin SF; Blemings A; Goodman SG; Evans CP; Nilsson J; Bhatt DL; Zubovskiy K; Olesen TK; Dugi K; Clarke NW; Higano CS; Roe MT;
    JACC CardioOncol; 2020 Mar; 2(1):70-81. PubMed ID: 34396210
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Degarelix acetate for the treatment of prostate cancer.
    Klotz L
    Drugs Today (Barc); 2009 Oct; 45(10):725-30. PubMed ID: 20069136
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Degarelix monotherapy compared with luteinizing hormone-releasing hormone (LHRH) agonists plus anti-androgen flare protection in advanced prostate cancer: an analysis of two randomized controlled trials.
    Iversen P; Damber JE; Malmberg A; Persson BE; Klotz L
    Ther Adv Urol; 2016 Apr; 8(2):75-82. PubMed ID: 27034720
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The efficacy and safety of degarelix, a GnRH antagonist: a 12-month, multicentre, randomized, maintenance dose-finding phase II study in Japanese patients with prostate cancer.
    Ozono S; Ueda T; Hoshi S; Yamaguchi A; Maeda H; Fukuyama Y; Takeda K; Ohashi Y; Tsukamoto T; Naito S; Akaza H
    Jpn J Clin Oncol; 2012 Jun; 42(6):477-84. PubMed ID: 22457321
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Experience with degarelix in the treatment of prostate cancer.
    Shore ND
    Ther Adv Urol; 2013 Feb; 5(1):11-24. PubMed ID: 23372607
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The effect of baseline testosterone on the efficacy of degarelix and leuprolide: further insights from a 12-month, comparative, phase III study in prostate cancer patients.
    Damber JE; Tammela TL; Iversen P; Abrahamsson PA; Boccon-Gibod L; Olesen TK; van der Meulen E; Persson BE
    Urology; 2012 Jul; 80(1):174-80. PubMed ID: 22748873
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A review of clinical evidence to assess differences in efficacy and safety of luteinizing hormone-releasing hormone (LHRH) agonist (goserelin) and LHRH antagonist (degarelix).
    Bahl A; Rajappa S; Rawal S; Bakshi G; Murthy V; Patil K
    Indian J Cancer; 2022 Mar; 59(Supplement):S160-S174. PubMed ID: 35343199
    [TBL] [Abstract][Full Text] [Related]  

  • 37. In search of the molecular mechanisms mediating the inhibitory effect of the GnRH antagonist degarelix on human prostate cell growth.
    Sakai M; Martinez-Arguelles DB; Patterson NH; Chaurand P; Papadopoulos V
    PLoS One; 2015; 10(3):e0120670. PubMed ID: 25811175
    [TBL] [Abstract][Full Text] [Related]  

  • 38. New treatment paradigm for prostate cancer: abarelix initiation therapy for immediate testosterone suppression followed by a luteinizing hormone-releasing hormone agonist.
    Garnick MB; Mottet N
    BJU Int; 2012 Aug; 110(4):499-504. PubMed ID: 22093775
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy and safety of androgen deprivation therapy after switching from monthly leuprolide to monthly degarelix in patients with prostate cancer.
    de la Rosette J; Davis R; Frankel D; Kold Olesen T
    Int J Clin Pract; 2011 May; 65(5):559-66. PubMed ID: 21342376
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Gonadotropin-releasing hormone antagonists versus standard androgen suppression therapy for advanced prostate cancer A systematic review with meta-analysis.
    Kunath F; Borgmann H; Blümle A; Keck B; Wullich B; Schmucker C; Sikic D; Roelle C; Schmidt S; Wahba A; Meerpohl JJ
    BMJ Open; 2015 Nov; 5(11):e008217. PubMed ID: 26567252
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.